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Whooping coughAbstract Aim and objective: The aim of the study was the evaluation of puriﬁed HLT from
B. pertussis vaccine strain 134 by employing indigenous technology and examining the
immuno-biochemical aspects of the puriﬁed protein.
Materials and methods: Shaker cultivation of B. pertussis strain 134, sterility, opacity conﬁrmation,
TCA precipitation of cellular proteins, G50 puriﬁcation subsequent DEAE puriﬁcation, purity
analysis, speciﬁc activity of HLT, and immune response analysis.
Results: The shaker cultivated B. pertussis strain 134 passed its quality attributes such as sterility,
opacity and purity. During TCA precipitation the B. pertussis desired proteins were precipitated
and conﬁrmed. The indigenous bed height was optimized and recovery was also calculated in
G50 puriﬁcation. The fractions were analyzed for OD, the total protein concentration and the
results were 0.074–0.214, and the total protein content was found between 12.33 lg/ml and
35.67 lg/ml. Subsequent DEAE puriﬁcation of selected G50 fractions was done and the fractions
9 and 14 had higher OD values of 0.675 and 0.397. Furthermore the DEAE puriﬁed samples were
structurally analyzed through SDS PAGE and it was found that HLT in the single polypeptide
band was around 140 kDa. The qualitative immune response analysis of DEAE puriﬁed selected
fractions pool showed positive immune response in ODD assay, and in the case of guinea pig
antisera it led to the development of diagnostic kits such as ELISA and other vital techniques.
108 K.C. Shivanandappa et al.Here, in case of guinea pig experiment, the hemorrhagic necrosis analysis showed the necrosis on
the skin at the injection site.
Conclusion: The B. pertussis HLT could be puriﬁed through two phase with G50 and DEAE, cost
effective techniques, the G50 puriﬁcation has reduced the bioburden problems during DEAE puriﬁ-
cation and at the same time the quality of the product was high.
ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
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nd/4.0/).1. Introduction
Pertussis, also known as whooping cough, is a highly infec-
tious and communicable disease caused by a gram-negative
bacterium Bordetella pertussis. Being an important cause of
death in infants and adolescents worldwide, it still continues
to be a public health concern, even in countries with high vac-
cine coverage. Estimates from WHO suggest that, there are 16
million cases reported about 195,000 deaths per year, 95% of
these cases are prevalent mostly in the developing nations.1
The disease is characterized by the intense paroxysmal
coughing, which terminates in an inspiratory ‘‘whoop sound’’.2
Whole cell pertussis vaccine (Wcpv) is a suspension of killed B.
pertussis organisms and has been used worldwide for nearly
90 years for the universal immunization of children. To control
whooping cough disease, it is used in combination with diph-
theria and tetanus vaccines, commonly known as DTP vaccine.
B. pertussis organism produces a wide range of biologically
active components called virulence factors, which contributes
to the ability of the organism to cause the disease. These viru-
lence factors are Pertussis Toxin (PT), Adenylate Cyclase
Toxin (ACT), Filamentous Haemagglutinin (FHA),
Lipopolysaccharide (LPS), Pertactin (PRN) (69 kDa),
Agglutinogens and Heat Labile Toxin (HLT).
Each of the virulence factors has its own role in immuno-
genicity and the biological property of the ﬁnal pertussis vac-
cine component. The Heat Labile Toxin (HLT) is one
among the virulence factors of B. pertussis, which may play
an important role in Bordetellosis, since this toxin is one of
only two toxins known to be produced by all virulent
Bordetella species. Bordet and Gengou3 who were the ﬁrst to
describe the action of this toxin, noted that B. pertussis cells
were dermonecrotizing and lethal, when injected into ani-
mals.4,5 The HLT is a cytoplasmic protein present in all
Bordetella species. The activity of the toxin is detoxiﬁed by
heat inactivation at 56 C for 30 min during Wcpv prepara-
tion. Therefore, the aim of the study was the evaluation of
puriﬁed HLT from B. pertussis vaccine strain 134 by employ-
ing indigenous technology and examining the immuno-
biochemical aspects of the puriﬁed protein.2. Materials and methods
2.1. Strain of B. pertussis
B. pertussis vaccine strain 134 (Rijks institute, Bilthoven,
Holland) was used in this study. The strain was maintained
in lyophilized state at 4 C and is an important strain used
for the production of routine Wcpv.2.2. Bordet-Gengou (BG) medium
Bordet-Gengou (BG) Medium was prepared as per
Cruikshank6 with the signiﬁcant modiﬁcations as prescribed
by WHO.7
2.3. B2 culture medium
The B2 culture medium was prepared with following composi-
tions: Bacto casamino acid (BCA) 1800 g, L-glutamic acid
1500 g, NaCl 750 g, KH2PO4 150 g, MgSO4 30 g, CaCl2 3 g,
FeSO4 3.74 g, CuSO4 0.15 g, Glutathione 3.05 g, yeast extract
1500 g, and soluble starch 450 g. Starch solution was prepared
by dissolving starch in cold water. The suspension was then
added to 20 l of hot distilled water and steamed in autoclave
at 118 C for 20 min separately. The remaining chemicals were
dissolved in serial order in 50 l of warmed distilled water in
separate vessel. L-glutamic acid solution was prepared by
dissolving in 50% NaOH to get amorphous solution in
warm distilled water. BCA was dissolved in 10 l of distilled
water and yeast extract was added to this solution. Finally
L-glutamic acid solution and other chemicals were added,
made up to 300 l and mixed properly, then it was transferred
to the fermentor and the medium was sterilized at 121 C for
30 min.8
2.4. Sterility media
Nutrient agar medium, Soyabean Caesin Digest Medium
(SCDM) and Alternate Thio glycolate medium (ATGM) were
used to study the purity and sterility of the culture at the
appropriate stage to ensure its purity and safety.
2.5. Preparation of seed culture
One ampoule freeze dried working seed stock (134 strain) was
opened under sterile environment and resuspended in 2 ml of
sterile B2 medium. The suspension was then inoculated in
BG slope and incubated at 35 C± 1 C for 72 h, and the pur-
ity was ensured by Gram staining. Furthermore, the culture
was scraped at aseptic conditions and inoculated into a 1 l
ﬂask containing 400 ml of B2 medium. The ﬂasks were loaded
on seed shaker for 24-h at 35 C± 1 C. Further ﬂasks were
loaded on shakers (140 ± 10 RPM) and sterile ﬁlters were
applied over the surface of the medium (3–5 Lpm).
Cultivation was allowed to continue for 30–36 h until the max-
imum yield of organism was achieved. Samples were collected
and checked for purity, opacity and pH. The pH should range
from 7.8 to 8.2.
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The purity and morphology were studied by Gram staining
method. The purity of seed samples during fermentor culture
was also checked by taking 1 ml of seed sample and inoculat-
ing it into 3-nutrient agar slopes. The other three slopes were
kept as control without adding any sample and both control
and test samples were incubated at 35 C± 1 C for 24 h
and observed for sterility. Samples (1 ml) of vaccines are inoc-
ulated into 4 bottles (100 ml each) of thioglycolate medium
and Soya bean Caesin Digestive medium. Four bottles of
Thioglycolate medium were incubated at 35 C and other 4
bottles were incubated at 20–22 C for 14 days.
2.7. Cell mass determination (opacity test)
0.5 ml of the test vaccine was taken in the opacity tube and
diluted the sample with normal saline until the opacity was
identical with 5th International reference preparation of opac-
ity (5th IRP) when compared by eye under uniform back-
ground, taking the dilution factor into account, and opacity
was calculated.9
2.8. Puriﬁcation of B. pertussis proteins
100 ml of B. pertussis was clariﬁed through centrifugation for
10 min at 6000 rpm in a cooling condition. The pellet was col-
lected and subsequently precipitated with 5% of TCA for
15 min at the ambient temperature (+18 to 22 C). TheM – Marker KDa
1- DEAE eluted pooled fractions (9 and 14) 
2- TCA precipitated B.pertussis supernatant 
3- Centrifuged pellet of B.Pertussis 
Figure 1 SDS–PAGE analysis of DEAE puriﬁed B. pertussis
(134).supernatant was taken and analyzed for total protein concen-
tration and OD absorbance tests.
2.9. Preparation of column chromatography for gel ﬁltration and
processing of B. pertussis
A 1.5 cm diameter thickened (Borosil), two-sided open glass
tube was taken for Sephadex 50 (G50) (Pharmacia, Uppsala,
Sweden) matrix (Fig. 1). The bottom side was connected with
silicon tubing, and the lower bed was made with Teﬂon coated
perforated neoprene O rings. The surface was covered with
muslin cloth and cellulose acetate hydrophilic membranes
(0.45 and 0.22 lm). Prior to usage, it was checked for leakage.
Subsequently 10 g of G50 matrix was weighed and dissolved in
buffer A (100 mM NaCl in 15 mM PBS) and the slurry was
degassed and loaded with the help of glass rod to the column,
while pouring the outlet was blocked at starting time and then
later it was opened with controller.
The bed height was optimized at various heights with differ-
ent bed volumes. Furthermore, the B. pertussis, TCA precipi-
tated, centrifuged supernatant was diluted with 1:10 with
buffer A. Around 10 ml of the material was loaded to the
G50 column. Prior to loading the G50 column was equili-
brated with 300 ml of buffer A for equilibrations. Once this
was achieved, the run was started. 2 ml volume of 15 fractions
was eluted, labeled and stored at +4 C until further use. The
condition of the run must be +4 C because the pertussis pro-
teins are heat labile. Three consecutive runs were conducted
for each G50 experiment.
2.10. Puriﬁcation of HLT
G50 puriﬁed fractions were analyzed for its qualities through
optical absorbance, and total protein SDS. The selected frac-
tions were pooled and estimated for the total proteins. It was
loaded to the DEAE matrix in the column of
150 mm · 1000 mm, with bed height and bed volume of
45 mm and 60 ml, respectively. The puriﬁcation procedure
was conducted at 4 C, the column was equilibrated with
100 mM NaCl in 15 mM PBS pH 7.5, and the proteins were
eluted with the elution buffers (buffer B-15 mM PBS in
300 mM NaCl and buffer C-15 mM PBS in 600 mM NaCl)
and were eluted at a ﬂow rate of 75 ml/h. The eluted fractions
(2 ml) were assayed for absorbance at 280 nm and for
ischemia-inducing activity.
2.11. Analysis of puriﬁed protein
The SDS–PAGE was analyzed as per Laemmli et al.10 with sig-
niﬁcant modiﬁcations in a vertical electrophoresis Unit (Bio-
Rad Laboratory USA). Samples were loaded in the wells
and the gel was run at 180 V. After the tracking dye reached
the bottom, the gel was removed gently and silver stained.
The gel was submerged in ﬁxative and left overnight (50%
methanol, 12% Glacial Acetic Acid, 37 ll formaldehyde). It
was then impregnated in Sodium thiosulphate –
Na2S2O3Æ5H2O (0.02 gm%). Finally, the gel was treated with
the developer (6% Na2CO3, 40 ll of 0.02 gm% Sodium
Thiosulphate – Na2S2O3Æ5H2O, 10 ll of formaldehyde). Once
the gel was stained, it was stored in storing solution (50%
methanol, 12% Glacial Acetic Acid).
Table 1 Total protein analysis.
S. no. Sample OD value (280 nm) Protein
concentration (lg)
1 Crude (neat) 1.245 207.5
2 Crude (1:10) 0.160 26.66
3 TCA(s) 1.635 272.5
4 TCA(p) 0.028 4.67
Table 2 Bed height analysis for the optimal recovery of
pertussis protein.
S. no. Height of
the gel (cm)
Peak analysis OD
280 nm
Total protein
concentration (lg)
1 2 Asymmetry 1.402 233.6
2 4 Symmetry 1.802 300.3
3 6 Symmetry 1.902 317
4 8 Asymmetry 2.102 350
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The total protein was calculated by Lowry’s method.11
2.13. Qualitative estimation of proteins by absorbance
The absorbances of the protein solution were measured and
the A260/A280 values for the protein samples were calculated
and compared with the standard values.12
2.14. Measurement of ischemia-inducing activity of HLT
DEAE puriﬁed selected fraction samples were qualitatively
checked (100 ll) for an ischemic inducing activity in guinea
pigs (Hartley female guinea pigs’ weight range between 300
and 350 g), and the samples were further diluted with PBS
pH 7.2, and administrated to guinea pigs intracutaneously.
The activity was observed after 24 h.
2.15. Analysis of immune response
Animals were immunized through intramuscular route: the
DEAE puriﬁed pooled fractions with Fraund’s complete adju-
vant. As an adjuvant on primary dose the booster on the 7th
day was observed. On 14th day venous blood ranging from 3
to 5 ml was collected from the Guinea pigs. The collected
blood was kept at room temperature until coagulation was
noticed. This was followed by incubation at 35 C for
30 min, and storage at 4 C for 24 h. The serum was removed
by centrifugation and 0.01% thiomersal was added as
preservative.
2.16. Ouchterlony’s double immunodiffusion (ODD)
Guinea pigs were immunized subcutaneously with puriﬁed
protein for 1 week intervals. The blood samples were collected
and the serums were separated in sterile condition. The serum
samples were taken for ODD assay.13 Four wells, 3 mm in
diameter and 1 cm in distance from each other, were made
on the agarose plate. The gel was allowed to solidify at room
temperature and the wells were punched using a gel punch,
resulting in corresponding pairs of wells. Next, 15 ll of anti-
serum and B. pertussis (134) was added into each well and
was left standing for 3 days in a humid atmosphere at 37 C.
The precipitation line was observed using a scattered light
illuminator.
3. Results and discussion
The B. pertussis vaccine seed strain 134 was subcultured asep-
tically on BG medium. After the seed growth it was conse-
quently propagated in shaker culture employed with B2
broth medium and the sterility of the culture medium was
ensured. Before analysis with chromatography technique, the
B. pertussis culture was precipitated with TCA. Prior to this,
culture was clariﬁed by centrifugation at 6000 rpm for one
hour in cooling conditions (to avoid protein loss).
Subsequently, the supernatants and pellets of precipitatedTCA were stored and OD was taken for (A) culture neat,
(B) 1:10 diluted sample of the culture, (C) crude TCA super-
natants and (D) TCA pellets and were evaluated for OD at
280 nm and the values are found to be 1.245, 0.160, 1.635
and 0.028 respectively.
The crude and TCA supernatants showed higher OD values
which represent the amount of protein present (Table 1). This
was also reﬂected in the total protein quantiﬁcation (207.5 and
272.5 lg respectively). These proteins may also contain several
virulence factors’ proteins of B. pertussis such as PT, FHA,
Fimbriae, PRN, ACT, HLT and endotoxins.
When the column of 4 cm (6 ml of bed volume of Sephadex
G50) was used, the puriﬁcation peak analysis of pertussis pro-
teins and the level of impurities were found to be in symmetry
which indicated the maximal recovery of bacterial proteins and
the removal of maximal quantity of impurities. At that same
time the OD values of all the different heights of the matrix
was found to be 1.402, 1.802, 1.902 and 2.102 respectively,
the total protein concentrations of the columns were 233.6,
300.3, 317 and 350 lg/ml. In this experiment, the 4 cm height
peak was symmetry and the total protein was also higher when
comparing with others (Table 2).
3.1. G50 puriﬁcation
The TCA precipitated B. pertussis cell supernatant was loaded
to the 4 cm bed height of the G50 column, and prior to loading
the cell extract was mixed with loading buffer (buffer A). The
ratio of the crude and buffer was 1:1; this was loaded and the
prime puriﬁcation was done by the principle of speciﬁc gravity
of 20 ml of the material and was subjected to 2 ml of fraction
volume. A total of 15 fractions were collected by additional
loading of buffer A. All the fractions were analyzed at
280 nm: OD, total protein content by Lowry’s method, and
the OD values ranged between 0.074 and 0.214, and the total
protein content range between 12.33 lg/ml and 35.67 lg/ml.
Out of 15 fractions, 5 fractions were selected based on the pro-
tein concentration as well as the OD values for further DEAE
puriﬁcation.
Centre Well Pertussis immune sera (14th day)
Well-1  B.Pertussis (134) centrifuged pellet 
Well-2 DEAE eluted pooled fractions (9 and 14) 
Well-3  Negative Control (PBS)
Well-4 TCA precipited B.pertussis supernatant 
Figure 3 ODD assay for DEAE puriﬁed B. pertussis (134).
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G50 puriﬁed selected fractions (5 numbers) were further sub-
jected to DEAE puriﬁcation. The fractions were pooled and
diluted with buffer A (equal volume) and loaded to 5 cm bed
height DEAE (10 g/ml bed volume) column. A total of 19 frac-
tions were eluted and the absorbance was analyzed.
The fractions 9 and 14 had the higher OD values of 0.675
and 0.397 respectively when compared with other fractions.
The fraction 9 was eluted by the 300 mM of NaCl Strength
buffer. In case of fraction 14, it was eluted with 600 mM
NaCl strength. All the fractions were additionally focused on
total protein content by Lowry method. The values tabulated
were (Fig. 2) 112.5 lg/ml and 66.1 lg/ml of total protein
content of fractions 9 and 14 respectively.
3.3. Analysis of puriﬁed protein
DEAE puriﬁed HLT proteins from culture were subjected to
SDS–PAGE analysis which gives a clear molecular mass of
140 kDa (Fig. 1). Similarly, the crude fraction showed different
molecular bands ranging from 40 kDa to 205 kDa. This result
indicates that apart from HLT (140 kDa), the pertussis vaccine
also contained other virulence factors with different molecular
weight. Although some contamination was observed on SDS
gels at low molecular weight, it is likely that this resulted in
part from nicking of the intact toxin molecule by proteolytic
enzymes. Molecular size gave variable results, probably
because of extraordinary biological activity of the HLT.
HLT is reported to be serologically related, and molecular
weights of 102,00014 and 190,00015 for the HLT of Bordetella
bronchiseptica have been reported by different investigators.
3.4. ODD assay
The antiserum raised against puriﬁed HLT in guinea pigs
showed that in ODD assay, serum obtained was tested for
reactivity against speciﬁc antigens by immunodiffusion.
Immune sera were tested against DEAE puriﬁed HLT applied
to the wells (1, 2 and 4). Wells 1, 2 and 4 contained 10 ll of
culture centrifuged pellet, pooled DEAE puriﬁed fractions
(fractions 9 and 14) and TCA precipitated culture. Well 3 con-
tained PBS, the center well contained immune serum after dif-
fusion, and the gels were ﬁxed and stained with coomassie blue
(Fig. 3). The qualitative immunogenicity shown in this test wasFigure 2 Analysis DEAE puriﬁed B. pertussis fractions.of superior quality compared to all three samples, especially
the DEAE pooled materials diffusion line is thicker and the
other samples are showing positive.
This result indicated that the guinea pig is an ideal labora-
tory animal for the preparation of antiserum against HLT.
3.5. Ischemic inducing activity
Ischemia-inducing activity of DEAE puriﬁed HLT from B.
pertussis strain 134 Samples (100 ll) of an HLT preparation
which had been diluted logarithmically in phosphate-
buffered saline, pH 7.2. These were injected intracutaneously
into the shaved back of female Hartley guinea-pigs weighed
300–350 g and showed colored lesions, ranging from light red-
dish (erythema) to purple (hemorrhagic necrosis) after 24 h
(Fig. 4). The minimum quantity of protein producing anFigure 4 Ischemic inducing activity of guinea pig after 24 h.
112 K.C. Shivanandappa et al.ischemic lesion 10 mm in diameter, is deﬁned as the minimum
ischemia-inducing dose (MID).16 The similar studies by
Kurokawa et al. (1969), in their experiments showed that the
HLT preparations which induced hemorrhagic lesions in gui-
nea pigs produced ischemic lesions in rabbits either with or
without haemorrhage.17 Thus, rabbits appeared to be less sus-
ceptible than guinea pigs to the hemorrhagic action of crude
HLT preparations.
Nakase and Endoh (1985) in their study reported that, the
dermonecrotic toxin activity of B. pertussis inhibits a
Na+-k+-ATPase in vitro assay and causes contraction of
the smooth muscle surrounding peripheral blood vessels,
resulting in vasoconstriction and increased perfusion pressure
in perfused lungs from guinea pigs.14,18
4. Conclusion
Pertussis vaccine has been used for nearly 9 decades world-
wide for the universal immunization of children to control
whooping cough disease. The vaccine is usually administered
in the National Childhood Program as a combined vaccine
DTwP or DTaP. B. pertussis organism produces several viru-
lence factors such as PT, ACT, and FHA, including endo-
toxin and Heat Labile Toxin (HLT). Each virulence factor
has their own role of immunogenicity and biological property
in the ﬁnal WCpV vaccine. So far there has been little sys-
tematic and quantitative study of HLT by different strains
of B. pertussis under different culture conditions. The mech-
anism action of HLT is unknown and possible involvement
of HLT in pathogenesis of pertussis is also unclear. In this
study we puriﬁed the HLT through two stages such as
G50, subsequently with DEAE technique as indigenously
developed. The HLT was assessed through SDS–PAGE and
showed molecular weight 140 kDa as a single polypeptide.
Furthermore, the immunogenicity was also analyzed. ODD
revealed its high-quality and the guinea pigs sera were
obtained against DEAE. Puriﬁed pooled fractions were used
as diagnostic purposes viz., antibodies and development of
ELISA kit. In addition, toxicity assessment in guinea pig
study found that HLT induced hemorrhagic lesions at the
injection site around 10 mm thickness. The crude puriﬁed
toxin produced whole range of hemorrhagic and ischemic
inducing activity in the guinea pig experiment found that
the HLT has an intracellular location. It is necessary to dis-
rupt the activity of toxin in the course of vaccine preparation.
Hence, HLT should be detoxiﬁed by heat inactivation at
56 C for 30 min, which is the most prepared method during
Wcpv production. From this study, it is concluded that the
toxoid HLT plays a signiﬁcant role in the pathogenic activity
in laboratory animals. Therefore, the careful evaluation of
each toxin during the development of new and safer vaccines
is important. In this attempt, we puriﬁed the HLT using
indigenous technique, to evaluate a suitable vaccine which
is capable of eliciting protective immune responses after pass-
ing standard quality and safety tests. The implementation of
these assays will contribute to the enhanced and safer activity
of future vaccines.
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